BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28910431)

  • 1. HLA-Mismatched Microtransplant in Older Patients Newly Diagnosed With Acute Myeloid Leukemia: Results From the Microtransplantation Interest Group.
    Guo M; Chao NJ; Li JY; Rizzieri DA; Sun QY; Mohrbacher A; Krakow EF; Sun WJ; Shen XL; Zhan XR; Wu DP; Liu L; Wang J; Zhou M; Yang LH; Bao YY; Dong Z; Cai B; Hu KX; Yu CL; Qiao JH; Zuo HL; Huang YJ; Sung AD; Qiao JX; Liu ZQ; Liu TQ; Yao B; Zhao HX; Qian SX; Liu WW; Forés R; Duarte RF; Ai HS;
    JAMA Oncol; 2018 Jan; 4(1):54-62. PubMed ID: 28910431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
    Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
    Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up.
    Guo M; Hu KX; Liu GX; Yu CL; Qiao JH; Sun QY; Qiao JX; Dong Z; Sun WJ; Sun XD; Zuo HL; Man QH; Liu ZQ; Liu TQ; Zhao HX; Huang YJ; Wei L; Liu B; Wang J; Shen XL; Ai HS
    J Clin Oncol; 2012 Nov; 30(33):4084-90. PubMed ID: 23045576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
    Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
    J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Li WY; Wang Y; Chen SN; Qiu HY; Fu ZZ; Wu DP; Sun AN
    Leuk Lymphoma; 2018 Jul; 59(7):1652-1658. PubMed ID: 29043875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
    Canaani J; Savani BN; Labopin M; Michallet M; Craddock C; Socié G; Volin L; Maertens JA; Crawley C; Blaise D; Ljungman PT; Cornelissen J; Russell N; Baron F; Gorin N; Esteve J; Ciceri F; Schmid C; Giebel S; Mohty M; Nagler A
    Am J Hematol; 2017 Aug; 92(8):789-796. PubMed ID: 28439910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical
    Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
    Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research on the clinical effect and in vitro study of HLA-mismatched hematopoietic stem cell infusion for acute myeloid leukemia.
    Zhang R; Zhao F; Wang J
    Hematology; 2015 Dec; 20(10):555-60. PubMed ID: 26067370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
    Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
    Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
    Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
    Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
    Brissot E; Labopin M; Stelljes M; Ehninger G; Schwerdtfeger R; Finke J; Kolb HJ; Ganser A; Schäfer-Eckart K; Zander AR; Bunjes D; Mielke S; Bethge WA; Milpied N; Kalhs P; Blau IW; Kröger N; Vitek A; Gramatzki M; Holler E; Schmid C; Esteve J; Mohty M; Nagler A
    J Hematol Oncol; 2017 Jun; 10(1):130. PubMed ID: 28646908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia.
    Tao S; Zhou D; Song L; Deng Y; Chen Y; Ding B; He Z; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2231733. PubMed ID: 37408450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study.
    Yu S; Huang F; Wang Y; Xu Y; Yang T; Fan Z; Lin R; Xu N; Xuan L; Ye J; Yu W; Sun J; Huang X; Liu Q
    Leukemia; 2020 May; 34(5):1433-1443. PubMed ID: 31831845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
    Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
    J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
    Lorentino F; Labopin M; Bernardi M; Ciceri F; Socié G; Cornelissen JJ; Esteve J; Ruggeri A; Volin L; Yacoub-Agha I; Craddock C; Passweg J; Blaise D; Gedde-Dahl T; Poiani M; Fegueux N; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1236-1244. PubMed ID: 30058714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
    Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
    J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.